RHJA
TVTX icon

Rice Hall James & Associates’s Travere Therapeutics TVTX Stock Holding History

Rice Hall James & Associates’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.76M Buy
92,757
+1,221
+1% +$36.5K 0.15% 140
2025
Q4 		$3.5M Buy
91,536
+7,439
+9% +$242K 0.19% 116
2025
Q3 		$2.01M Sell
84,097
-9,515
-10% -$179K 0.11% 161
2025
Q2 		$1.39M Buy
93,612
+4,995
+6% +$82.8K 0.07% 187
2025
Q1 		$1.59M Sell
88,617
-4,041
-4% -$82K 0.09% 178
2024
Q4 		$1.61M Sell
92,658
-2,078
-2% -$36.8K 0.09% 190
2024
Q3 		$1.33M Buy
94,736
+18,562
+24% +$193K 0.07% 198
2024
Q2 		$626K Buy
76,174
+2,774
+4% +$18.7K 0.04% 220
2024
Q1 		$566K Buy
73,400
+3,140
+4% +$26.5K 0.03% 228
2023
Q4 		$632K Sell
70,260
-8,102
-10% -$59K 0.04% 236
2023
Q3 		$701K Sell
78,362
-1,481
-2% -$20.9K 0.04% 229
2023
Q2 		$1.23M Buy
79,843
+3,345
+4% +$60.8K 0.07% 205
2023
Q1 		$1.72M Buy
76,498
+290
+0.4% +$6.16K 0.1% 200
2022
Q4 		$1.6M Sell
76,208
-1,629
-2% -$34.5K 0.09% 210
2022
Q3 		$1.92M Sell
77,837
-24,154
-24% -$624K 0.11% 190
2022
Q2 		$2.47M Buy
101,991
+2,428
+2% +$61.1K 0.12% 172
2022
Q1 		$2.57M Buy
99,563
+3,387
+4% +$89.9K 0.1% 188
2021
Q4 		$2.98M Sell
96,176
-13,030
-12% -$367K 0.11% 176
2021
Q3 		$2.65M Buy
109,206
+2,379
+2% +$43.7K 0.1% 159
2021
Q2 		$1.56M Sell
106,827
-5,073
-5% -$100K 0.06% 233
2021
Q1 		$2.79M Buy
111,900
+36
+0% +$995 0.09% 156
2020
Q4 		$3.05M Buy
+111,864
New +$2.61M 0.11% 141

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rice Hall James & Associates's TVTX Position: Q1 2026 in Review

Rice Hall James & Associates increased its Travere Therapeutics (TVTX) stake by 1.3% in Q1 2026, buying an estimated $36.5K and bringing the position to 92,757 shares worth $2.76M. The position accounts for 0.15% of the portfolio, ranked #140.

Rice Hall James & Associates first reported a position in TVTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $3.5M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Rice Hall James & Associates held 92,757 shares of Travere Therapeutics worth $2.76M as of Q1 2026.
  • Rice Hall James & Associates bought 1,221 Travere Therapeutics shares in Q1 2026, an estimated $36.5K.
  • Travere Therapeutics made up 0.15% of Rice Hall James & Associates's portfolio in Q1 2026, its #140 holding.
  • Rice Hall James & Associates first reported a position in Travere Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Rice Hall James & Associates's Travere Therapeutics position peaked at $3.5M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.